RecruitingNot ApplicableNCT02605785
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
Sponsor
Mayo Clinic
Enrollment
332 participants
Start Date
Nov 1, 2015
Study Type
INTERVENTIONAL
Conditions
Summary
This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).
Eligibility
Min Age: 35 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called F-18 AV 1451 for people with progressive supranuclear palsy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 35 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGF-18 AV 1451
Tau PET scan
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02605785
Related Trials
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
NCT032251441 location
Neurologic Stem Cell Treatment Study
NCT027950523 locations
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders
NCT075702121 location
The Swedish BioFINDER 2 Study
NCT031749382 locations
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
NCT038721021 location